Future investigations should therefore validate these findings in additional breast cancer subtypes, such as MDA-MB-231 (triple-negative) and SK-BR-3 (HER2-positive) cell lines, to ensure broader applicability across diverse tumor phenotypes. This evidence concerns the gene ERBB2 and neoplasm.